
Ariela Hoxha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1312893/publications.pdf Version: 2024-02-01



Δριείλ Ησχηλ

#	Article	IF	CITATIONS
1	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	1.4	573
2	Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology, 2011, 50, 1684-1689.	1.9	193
3	Antiphospholipid antibody profile based obstetric outcomesÂof primary antiphospholipid syndrome: theÂPREGNANTS study. American Journal of Obstetrics and Gynecology, 2017, 216, 525.e1-525.e12.	1.3	131
4	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	5.8	106
5	Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmunity Reviews, 2017, 16, 173-178.	5.8	71
6	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	3.4	62
7	Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study. Journal of Rheumatology, 2013, 40, 425-429.	2.0	54
8	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology, 2020, 59, 1306-1314.	1.9	53
9	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. Journal of Rheumatology, 2017, 44, 1165-1172.	2.0	51
10	Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. Journal of Reproductive Immunology, 2016, 115, 14-19.	1.9	49
11	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 890-898.	2.3	49
12	A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmunity Reviews, 2013, 12, 768-773.	5.8	41
13	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	3.8	40
14	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Frontiers in Cardiovascular Medicine, 2019, 6, 11.	2.4	39
15	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clinica Chimica Acta, 2015, 446, 201-205.	1.1	38
16	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	5.8	38
17	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 901-908.	3.4	37
18	Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. Journal of Clinical Apheresis, 2012, 27, 200-204.	1.3	32

Ariela Hoxha

#	Article	IF	CITATIONS
19	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1083-9.	2.3	32
20	lgC phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thrombosis Research, 2019, 177, 157-160.	1.7	30
21	Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1265-70.	2.3	27
22	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. Journal of Autoimmunity, 2018, 93, 124-130.	6.5	26
23	Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine, 2017, 84, 169-173.	1.6	25
24	Plasma exchange effectively removes 52―and 60â€kDa antiâ€Ro/SSA and anti‣a/SSB antibodies in pregnant women with congenital heart block. Transfusion, 2015, 55, 1782-1786.	1.6	24
25	Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. Journal of Rheumatology, 2018, 45, 1263-1272.	2.0	24
26	Therapeutic apheresis during pregnancy: A single center experience. Transfusion and Apheresis Science, 2019, 58, 652-658.	1.0	23
27	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. RMD Open, 2020, 6, e001340.	3.8	23
28	Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study. Clinical and Experimental Rheumatology, 2016, 34, 706-13.	0.8	23
29	Late development of complete atrioventricular block may be immune mediated and congenital in origin. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 275-281.	1.5	22
30	The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. Joint Bone Spine, 2016, 83, 167-171.	1.6	22
31	The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. Seminars in Arthritis and Rheumatism, 2021, 51, 28-35.	3.4	18
32	Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfusion and Apheresis Science, 2015, 53, 269-278.	1.0	17
33	Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients. Lupus Science and Medicine, 2016, 3, e000129.	2.7	16
34	The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints. Rheumatology International, 2016, 36, 443-446.	3.0	16
35	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 28-39.	6.5	16
36	The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thrombosis Research, 2015, 136, 883-886.	1.7	15

Ariela Hoxha

#	Article	IF	CITATIONS
37	Diagnosis and therapy of antiphospholipid syndrome. Polish Archives of Internal Medicine, 2015, 125, 672-677.	0.4	15
38	Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study. Reumatismo, 2020, 72, 125-130.	0.9	13
39	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	1.9	13
40	Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. Thrombosis and Haemostasis, 2020, 120, 036-043.	3.4	11
41	The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report. BMC Musculoskeletal Disorders, 2016, 17, 485.	1.9	9
42	Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block. Clinical Rheumatology, 2017, 36, 1155-1160.	2.2	9
43	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. Rheumatology Advances in Practice, 2019, 3, rkz005.	0.7	9
44	A contribution to detection of anticardiolipin and anti-β2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. Clinica Chimica Acta, 2015, 446, 93-96.	1.1	6
45	European families reveal MHC class I and II associations with autoimmune-mediated congenital heart block. Annals of the Rheumatic Diseases, 2018, 77, 1381-1382.	0.9	6
46	Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association?. Clinical Rheumatology, 2016, 35, 1885-1889.	2.2	5
47	Efficacy and Safety of Ultrasound-Guided Intra-articular Glucocorticoid Injection in Erosive Hand Osteoarthritis. Pain Medicine, 2021, 22, 1229-1232.	1.9	5
48	Fluorinated steroids are not superior to any treatment to ameliorate the outcome of autoimmune mediated congenital heart block: a systematic review of the literature and meta-analysis. Clinical and Experimental Rheumatology, 2020, 38, 783-791.	0.8	5
49	Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. Blood, 2021, 137, 2989-2992.	1.4	4
50	Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays. Clinical Chemistry and Laboratory Medicine, 2018, 56, 927-932.	2.3	2
51	Impact of disease duration and gender on the sensitivity and specificity of 2015 ACR/EULAR classification criteria for gout. Cross-sectional results from an Italian multicentric study on the management of crystal-induced arthritis (ATTACk). Clinical and Experimental Rheumatology, 0, , .	0.8	2
52	Diagnosis and therapy of antiphospholipid syndrome. Author's reply Polish Archives of Internal Medicine, 2015, 125, 786-786.	0.4	1
53	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). Clinical and Experimental Rheumatology, 2021, 39, 938-946.	0.8	1
54	High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets. Clinical and Experimental Rheumatology, 0, , .	0.8	1

#	Article	IF	CITATIONS
55	Obstetric Antiphospholipid Syndrome. , 0, , .		0
56	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	3.4	0